Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intelgenx Technologies Corp IGXT

IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.


GREY:IGXT - Post by User

Post by Betteryear2on Sep 07, 2021 9:35pm
426 Views
Post# 33823298

Market Launch of RIZAPORT® in Spain

Market Launch of RIZAPORT® in Spain

SAINT LAURENT, Quebec, Sept. 07, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercialization partner in the European Union (“EU”) for RIZAPORT®, a unique for the treatment of acute migraines, has launched the product in Spain.

RIZAPORT® is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms.1 RIZAPORT® is based on IntelGenx's proprietary VersaFilm® technology. It dissolves rapidly and releases its active ingredient in the mouth. The administration method of the RIZAPORT® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a therapeutic alternative for migraine patients, especially for those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population, and for patients suffering from dysphagia (difficulty swallowing).1

“This is the first VersaFilm®-based product to launch in the global pharmaceutical market and comes on the heels of IntelGenx’s recent transition to a commercial-stage company,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “The European migraine drug market is large and growing. It was valued at more than US$1 billion in 2019 and is expected to approach US$1.5 billion by 2024.2 We are looking forward to continuing to support Exeltis’ launch of RIZAPORT® in Spain, as well as its plans to bring this therapy to migraine patients in additional EU countries in the future.”

“We are excited to bring this innovative and easy-to-administer treatment to migraine patients in Spain,” said Alberto Fabregas, Managing Director of Exeltis Healthcare. “We are also looking forward to continued collaboration with IntelGenx, and to launching RIZAPORT® in additional markets.”


https://www.globenewswire.com/news-release/2021/09/07/2292923/0/en/IntelGenx-Announces-Market-Launch-of-RIZAPORT-in-Spain.html
<< Previous
Bullboard Posts
Next >>